Phase II clinical trial of chemotherapy-naive patients≥ 70 years of age treated with erlotinib for advanced non–small-cell lung cancer
DM Jackman, BY Yeap, NI Lindeman… - Journal of Clinical …, 2007 - ascopubs.org
Purpose This is a phase II, multicenter, open-label study of chemotherapy-naïve patients
with non–small-cell lung cancer (NSCLC) and age≥ 70 years who were treated with …
with non–small-cell lung cancer (NSCLC) and age≥ 70 years who were treated with …
[HTML][HTML] Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib
GM Clark, DM Zborowski, JL Culbertson… - Journal of Thoracic …, 2006 - Elsevier
Introduction Erlotinib (Tarceva®) has demonstrated a survival benefit in unselected patients
with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy. Because …
with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy. Because …
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study
YL Wu, JH Kim, K Park, A Zaatar, G Klingelschmitt… - Lung cancer, 2012 - Elsevier
Maintenance therapy, commenced immediately after the completion of first-line
chemotherapy, is a promising strategy for improving treatment outcomes in patients with non …
chemotherapy, is a promising strategy for improving treatment outcomes in patients with non …
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)
MH Cohen, JR Johnson, S Chattopadhyay… - The …, 2010 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
MH Cohen, JR Johnson, YF Chen, R Sridhara… - The …, 2005 - academic.oup.com
Abstract On November 18, 2004, erlotinib (Tarceva®; OSI Pharmaceuticals, Inc., Melville,
NY, http://www. osip. com, and Genentech, Inc., South San Francisco, CA, http://www. gene …
NY, http://www. osip. com, and Genentech, Inc., South San Francisco, CA, http://www. gene …
TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and …
7504 Background: Poor performance status (PS) NSCLC is an important, under-studied
group of lung cancer patients, affecting 30-40% of patients. We determined the role of …
group of lung cancer patients, affecting 30-40% of patients. We determined the role of …